Abeona completes enrollment of low-dose cohort for ABO-102 in phase 1/2 trial for MPS IIIA
Abeona Therapeutics announced enrollment has been completed for the low-dose cohort in its ongoing Phase 1/2 trial for ABO-102. The first-in-man clinical trial utilizes a single injection of AAV gene therapy for patients with MPS IIIA (Sanfilippo syndrome type A), a rare autosomal recessive disease. August 29, 2016